Date: 2016-01-04
Type of information: Nomination
Compound:
Company: Celyad (Belgium)
Therapeutic area: Cancer - Oncology - Cardiovascular diseases - Regenerative medicine
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 4, 2016, Celyad, a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, announced the appointment of Dr. Jean-Pierre Latere as Head of the Regenerative Medicine and Medical Device Franchise, effective January 4th, 2016. Dr Latere started his career as a Research Associate at the Michigan State University in the US. Following that assignment, he moved to the Johnson & Johnson group where he held various positions, from Scientist to Senior Scientist. He then joined Cardio3 BioSciences in 2008 as Project Manager Delivery System and left the company in 2012 in the position of Senior Director Business Development. Prior to joining Celyad, Jean-Pierre served as Beauty Care and Healthcare Market Global Leader at Dow Corning. Jean-Pierre holds a PhD in Chemistry from the University of Liège, Belgium.
Financial terms:
Latest news:
